Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Systemic Juvenile Idiopathic Arthritis

Rayfel Schneider, MBBCh, and Ronald M. Laxer, MDCM  |  Issue: May 2012  |  May 9, 2012

Systemic juvenile idiopathic arthritis (sJIA) only accounts for approximately 10% of all types of JIA, but has a disproportionately high morbidity compared with other subtypes. In most children, the disease begins with a severe systemic illness, characterized by fever, rash, and arthralgia or frank arthritis along with other characteristic features that include diffuse lymphadenopathy, hepatosplenomegaly, and serositis, especially pleuritis and pericarditis. Children often require admission to a hospital to facilitate the expeditious investigation of the presenting symptoms, to exclude potential diagnoses such as infections and malignancies, to document the characteristic quotidian fever pattern, and to initiate appropriate treatment. Criteria for the classification of sJIA are shown in Table 1.1 Typical laboratory features include anemia (usually hypochromic and microcytic), leukocytosis (sometimes with prominent leukemoid reactions with white blood cell counts >50,000), thrombocytosis, elevated immunoglobulins, erythrocyte sedimentation rate, and C-reactive protein (CRP), and hypoalbuminemia.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
click for large version
Table 1: Systemic JIA ILAR Classification Criteria1

There is a striking association of sJIA with secondary hemophagocytic lymphohistiocytosis, also known as macrophage activation syndrome (MAS). Although approximately 10% of sJIA patients develop overt MAS, up to 30% of children have evidence of subclinical MAS, characterized by a number of biochemical and immunological markers of MAS, including elevated levels of soluble CD163.2 In fact, some markers of MAS such as elevations of serum ferritin and d-dimers are considered typical laboratory manifestations of active systemic disease. It is interesting to note that both active sJIA and MAS are characterized by natural killer (NK) cell dysfunction. Full-blown MAS complicating sJIA is associated with significant morbidity and potentially mortality.

The following case represents a typical patient with early sJIA. We will present the case and discuss the treatment choices and outcome.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A child with systemic juvenile idiopathic arthritis and macrophage activation syndrome was found to have this pathognomonic hemophagocytic macrophage (center) in the peripheral blood. The macrophage has engulfed neutrophils, nucleated red cells, and cellular debris.

The Case

A 14-year-old boy was seen in the rheumatology clinic, having been unwell for approximately two months. He initially presented with diffuse arthralgias but subsequently developed fevers up to 102°F, usually once daily in the evening or early morning. He missed several days of school each week and estimated that he had lost 4 to 5 kg in weight. On physical examination, he had a typical systemic rash, diffuse lymphadenopathy, and oligoarthritis involving both wrists and one elbow. He did not have evidence of serositis or hepatosplenomegaly. After investigations excluded infections, malignancies, and other rheumatic diseases, a diagnosis of sJIA was made and he was treated with naproxen 500 mg bid. There was no improvement in his symptoms or laboratory markers when he was seen for a follow-up visit (see Table 2). Once the patient failed this initial nonsteroidal antiinflammatory drug (NSAID) trial, a decision had to be made about the next step in treatment.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Clinical Criteria/GuidelinesConditionsRheumatoid Arthritis Tagged with:AC&RAmerican College of Rheumatology (ACR)anti-inflammatorydrugJIAJuvenile idiopathic arthritismacrophage activation syndromeMethotrexatepatient carePediatricsrheumatologistSteroidstocilizumabTreatment

Related Articles

    ACR Issues sJIA Recommendations, SSc Classification Criteria

    October 1, 2013

    Guidelines address advances in pathophysiology and treatment of systemic juvenile idiopathic arthritis; criteria classify broader spectrum of systemic sclerosis

    Molecular Analysis Reveals Potential Treatment Window for Systemic Juvenile Idiopathic Arthritis

    January 2, 2013

    In patients with simultaneous systemic and arthritic components of systemic juvenile idiopathic arthritis (SJIA), these components appear to be related mechanistically. Moreover, the inflammatory pathways of SJIA appear to be distinct from those seen in polyarticular JIA.

    Manifestations of JIA: JIA-Associated Uveitis, sJIA & Lung Involvement in sJIA

    July 16, 2021

    JIA can manifest in a variety of ways. Experts discuss the implications of uveitis, systemic disease and lung involvement in sJIA.

    Large Group Study of Systemic JIA Patients Provides Insight into Disease Pathology

    January 25, 2016

    In a large group genetic analysis, researchers identified an association between the class II HLA region, including HLA-DRB1*11, and systemic juvenile idiopathic arthritis (sJIA), implicating adaptive immune molecules in sJIA’s pathogenesis and reinforcing its unique genetic position among JIA subtypes…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences